Dept of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Am J Clin Pathol. 2012 Jul;138(1):103-14. doi: 10.1309/AJCP88FZTWANLRCB.
The clinicopathologic and immunohistochemical features of 65 primary thymic carcinomas are reported (43 men and 22 women; 19-81 years old). Thymectomy was performed in all cases. Masaoka staging for 53 patients showed 3 patients in stage I, 14 in stage II, 17 in stage III, and 19 in stage IV. Histologic studies revealed 9 carcinoma subtypes. Immunohistochemically, the tumors showed high rates of expression for cytokeratin, Pax8, and FoxN1. Follow-up for 62 patients revealed that 36 patients were alive (mean follow-up, 51.1 months) and 26 had died (mean survival, 47.5 months). The 3- and 5-year overall survival rates were 76.6% and 65.7%, respectively. Our findings suggest that thymic carcinomas may behave less aggressively than commonly believed. Lymph node status and tumor size seem to be important prognostic factors. The Masaoka staging system does not seem to reliably predict outcome.
报告了 65 例原发性胸腺癌的临床病理和免疫组化特征（43 名男性和 22 名女性；年龄 19-81 岁）。所有病例均行胸腺切除术。53 例患者的 Masaoka 分期显示 3 例为Ⅰ期，14 例为Ⅱ期，17 例为Ⅲ期，19 例为Ⅳ期。组织学研究显示有 9 种癌亚型。免疫组化显示，肿瘤对细胞角蛋白、Pax8 和 FoxN1 的表达率较高。对 62 例患者的随访显示，36 例患者存活（平均随访时间 51.1 个月），26 例患者死亡（平均生存时间 47.5 个月）。3 年和 5 年总生存率分别为 76.6%和 65.7%。我们的研究结果表明，胸腺癌的行为可能不如普遍认为的那样具有侵袭性。淋巴结状态和肿瘤大小似乎是重要的预后因素。Masaoka 分期系统似乎不能可靠地预测预后。
